GM-CSF in Incompletely Resected or Recurrent Ependymoma

Pilot Study of the Effect of GM-CSF on Macrophages in Incompletely Resected or Recurrent Ependymoma

November 22, 2017

  • Clinical Trial Information

    Trial Contact: El-Shami, Jessica; Francois, Laetitia Claire; Leffin, Melissa; Spinelli, Jennifer

  • IRB No: 16.030.02

    Protocol Abbrev: 13-0133

    Principal Investigator: Amy A Smith, MD

    Sub Investigators: AguilarBonilla, Ana MD; Eslin, Don MD; Giusti, Vincent MD; Levy, Alejandro MD; Sutphin, Robert MD; Pope, Michele ARNP; Story, Allison ARNP; Sullivan Darden, Kelly ARNP

    Age Group: Pediatric

    Secondary Protocol No: 13-033

    Treatment: GM-CSF

    Applicable Disease Sites: Ependymoma

    Therapies Involved: Medication

  • Objective

    This study plans to learn more about the use of Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) on ependymoma tumors. The use of GM-CSF is a potential way of increasing the infiltration of immune cells and this study is looking at whether or not this will improve the outcome of patients with an ependymoma.